Wang Mian, Xin Yuanfeng, Cao Hao, Li Wanlu, Hua Yifei, Webster Thomas J, Zhang Chao, Tang Wenjie, Liu Zhongmin
Department of Cardiology, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Biomater Sci. 2021 Feb 21;9(4):1088-1103. doi: 10.1039/d0bm01164a. Epub 2020 Dec 17.
Studies of nanomedicine have achieved dramatic progress in recent decades. However, the main challenges that traditional nanomedicine has to overcome include low accumulation at target sites and rapid clearance from the blood circulation. An interesting approach using cell membrane coating technology has emerged as a possible way to overcome these limitations, owing to the enhanced targeted delivery and reduced immunogenicity of cell membrane moieties. Mesenchymal stem cell (MSC) therapy has been investigated for treating various diseases, ranging from inflammatory diseases to tissue damage. Recent studies with engineered modified MSCs or MSC membranes have focused on enhancing cell therapeutic efficacy. Therefore, bioengineering strategies that couple synthetic nanoparticles with MSC membranes have recently received much attention due to their homing ability and tumor tropism. Given the various membrane receptors on their surfaces, MSC membrane-coated nanoparticles are an effective method with selective targeting properties, allowing entry into specific cells. Here, we review recent progress on the use of MSC membrane-coated nanoparticles for biomedical applications, particularly in the two main antitumor and anti-inflammatory fields. The combination of a bioengineered cell membrane and synthesized nanoparticles presents a wide range of possibilities for the further development of targeted drug delivery, showing the potential to enhance the therapeutic efficacy for treating various diseases.
近几十年来,纳米医学研究取得了显著进展。然而,传统纳米医学必须克服的主要挑战包括在靶部位的低蓄积以及从血液循环中的快速清除。由于细胞膜部分增强的靶向递送和降低的免疫原性,一种使用细胞膜包被技术的有趣方法已成为克服这些限制的可能途径。间充质干细胞(MSC)疗法已被研究用于治疗从炎症性疾病到组织损伤的各种疾病。最近关于工程化修饰的间充质干细胞或间充质干细胞膜的研究集中在提高细胞治疗效果上。因此,将合成纳米颗粒与间充质干细胞膜相结合的生物工程策略最近因其归巢能力和肿瘤嗜性而备受关注。鉴于其表面存在各种膜受体,间充质干细胞膜包被的纳米颗粒是一种具有选择性靶向特性的有效方法,能够进入特定细胞。在此,我们综述了间充质干细胞膜包被的纳米颗粒在生物医学应用中的最新进展,特别是在抗肿瘤和抗炎这两个主要领域。生物工程化细胞膜与合成纳米颗粒的结合为靶向药物递送的进一步发展提供了广泛的可能性,显示出增强治疗各种疾病疗效的潜力。